Mumbai, Dec. 19 -- Zydus Lifesciences has signed an agreement with Myriad Genetics, a leader in molecular diagnostic testing and precision medicine company. Pursuant to the Agreement, Zydus will be introducing MyRisk(R) Hereditary Cancer Test, MyChoice(R) HRD Plus, Homologous Recombination Deficiency (HRD) Test and Prolaris(R) Prostate Cancer Prognostic Test to patients, clinicians, and healthcare systems across India.

Published by HT Digital Content Services with permission from Capital Market....